Carboplatin and irinotecan (CI) vs. carboplatin and etoposide (CE) for the treatment of extended-stage small-cell lung cancer in an elderly population: A phase II/III randomized control trial
Author:
Funder
National Cancer Center
Japan Agency for Medical Research and Development
National Cancer Center Japan
Publisher
Elsevier BV
Subject
Cancer Research,Pulmonary and Respiratory Medicine,Oncology
Reference15 articles.
1. Cancer Statistics 2021;Siegel;CA Cancer J. Clin.,2021
2. to 1997, with reference to time trends of lung cancer in the world;Morita;Jpn. J. Cancer Res.,1958
3. Treatment of small-cell lung cancer in elderly patients;Pallis;Cancer,2010
4. Randomized phase III trial ofcarboplatin plus etoposide vs. split doses of cisplatin plus etoposide in elderly or poor-risk patents with extensive disease small-cell lung cancer. JCOG 9702;Okamoto;Br. J. Cancer,2007
5. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer;Noda;N. Engl. J. Med.,2002
Cited by 5 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Drug combinations of camptothecin derivatives promote the antitumor properties;European Journal of Medicinal Chemistry;2024-09
2. Navigating first-line therapies for extensive-stage small-cell lung cancer: a frequentist network meta-analysis and systematic review;Future Oncology;2024-07-29
3. Comparison of Irinotecan/carboplatin versus Etoposide/carboplatin for extended disease small cell lung cancer (ED-SCLC): A systematic review and meta-analysis of randomized controlled trials;2024-03-07
4. Comment on: Carboplatin and irinotecan (CI) vs. Carboplatin and etoposide (CE) for the treatment of extended-stage small-cell lung cancer in an elderly population: A phase II/III randomized control trial;Lung Cancer;2023-12
5. A pharmacovigilance study of etoposide in the FDA adverse event reporting system (FAERS) database, what does the real world say?;Frontiers in Pharmacology;2023-10-26
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3